Maheux R, Lemay A, Blanchet P, Friede J, Pratt X
Research Centre, Hôpital St-François d'Assise, Quebec, Canada.
Hum Reprod. 1991 Apr;6(4):500-5. doi: 10.1093/oxfordjournals.humrep.a137367.
Ten pre-menopausal women with uterine leiomyoma were treated for 1 year with a monthly depot of luteinizing hormone-releasing hormone agonist (LHRA-a), goserelin, combined after the initial 3 months of treatment with conjugated oestrogens 0.3 mg (days 1-25) and medroxy-progesterone acetate 5 mg (days 16-25). Mean leiomyoma volume decreased by 49.3% during the first 3 months when goserelin alone was administered but did not change significantly during the 9 months of combination therapy. There were no significant changes in bone mass or high-density lipoprotein cholesterol during the study whereas hot flushes and menstrual blood loss were well controlled. These results indicate that ovarian suppression with a monthly depot of the LHRH-a, goserelin, combined after 3 months with low-dose hormonal replacement therapy reduced the size and the symptomatology of leiomyoma while preserving the bone mass.
十名患有子宫平滑肌瘤的绝经前女性接受了为期一年的治疗，每月注射一次促黄体生成素释放激素激动剂（LHRA-a）戈舍瑞林，在初始治疗的3个月后，联合使用0.3毫克结合雌激素（第1 - 25天）和5毫克醋酸甲羟孕酮（第16 - 25天）。在仅使用戈舍瑞林的前3个月，平滑肌瘤平均体积下降了49.3%，但在联合治疗的9个月期间没有显著变化。研究期间骨量和高密度脂蛋白胆固醇没有显著变化，而潮热和月经量得到了良好控制。这些结果表明，每月注射一次LHRH-a戈舍瑞林抑制卵巢功能，并在3个月后联合低剂量激素替代疗法，可减小平滑肌瘤的大小并缓解症状，同时保留骨量。
